EW vs KVYO · P/E 47, rev $3.39B vs rev $1.23B
Edwards Lifesciences Corp (EW) versus Klaviyo, Inc. (KVYO) — a side-by-side from cached financials, not a winner call.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Klaviyo, Inc. (KVYO) is a software - infrastructure company listed on US.
Latest reported EW revenue for 2026-06-30 was $3.39B. Net income was $622.6M. EW currently screens at market cap $49.91B and trailing P/E 46.9.
Latest reported KVYO revenue for 2025-12-31 was $1.23B. Net income was -$31.8M. Revenue was up 31.6% from 2024-12-31 to 2025-12-31. KVYO currently screens at market cap $9.88B.
EW currently screens at market cap $49.91B and trailing P/E 46.9. KVYO currently screens at market cap $9.88B.
Not investment advice. Open the EW and KVYO stock pages for the full models.
Not investment advice.